Organigram Global (NASDAQ:OGI) versus RxSight (NASDAQ:RXST) Critical Analysis

Organigram Global (NASDAQ:OGI) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Insider and Institutional Ownership

34.6% of Organigram Global shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 0.1% of Organigram Global shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Organigram Global and RxSight, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	0	1	2	0	2.67
RxSight	3	7	2	0	1.92

RxSight has a consensus target price of $8.17, indicating a potential upside of 69.90%. Given RxSight’s higher possible upside, analysts clearly believe RxSight is more favorable than Organigram Global.

Profitability

This table compares Organigram Global and RxSight’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organigram Global	28.14%	-13.39%	-8.67%
RxSight	-36.80%	-17.35%	-14.70%

Risk and Volatility

Organigram Global has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Earnings and Valuation

This table compares Organigram Global and RxSight”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$185.07 million	0.73	-$17.70 million	$0.46	2.09
RxSight	$134.48 million	1.49	-$38.94 million	($1.13)	-4.26

Organigram Global has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.

Summary

Organigram Global beats RxSight on 9 of the 13 factors compared between the two stocks.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

About RxSight

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.